These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 36470445)

  • 1. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
    Chen SD; Chuang YC; Lin TK; Yang JL
    Eur J Pharmacol; 2023 Jan; 938():175439. PubMed ID: 36470445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO; Glotfelty EJ; Li Y; Greig NH
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
    Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
    Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A; Goyal A
    Eur J Pharmacol; 2024 Nov; 982():176936. PubMed ID: 39182542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
    Shaefer CF; Kushner P; Aguilar R
    Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
    Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
    Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.